galapagos biotech
We are a fully integrated biotechnology company focused on discovering,
developing and commercializing innovative medicines. We are committed to
improving patients’ lives worldwide by targeting diseases with high unmet needs.
Our R&D capabilities cover multiple drug modalities, including small molecules
and cell therapies. Our portfolio comprises discovery through to Phase 4
programs in immunology, oncology, and other indications. Our first medicine for
rheumatoid arthritis and ulcerative colitis is approved and available in the
European Union, Norway, Great Britain, and Japan. Our mission is to develop
transformational medicines in areas of high unmet need by combining internal
with external science with the goal to add years of life and improve quality of
life of patients across the globe. Through the combined acquisition of CellPoint
and AboundBio, we are adding a new therapy and disease area to its current small
molecules portfolio: cell therapy, a potential transformative treatment of
different types of cancer. It propels us into next-generation cell therapies,
while significantly broadening our portfolio and capabilities. We employ more
than 1,300 employees worldwide, with sites in Belgium (international
headquarters), the Netherlands, France, Germany, Austria, Italy, Spain, the
Nordics, Switzerland, the UK and the US.
